Insulet Corporation(NASDAQ:PODD) the leader in tubeless insulin pump technology with its OmniPodĀ® Insulin Management System, divulged financial results for the three months and full year ended December 31, 2014.

Continuing to drive OmniPod adoption resulting in double digit year-over-year growth.

Strengthening senior leadership team with key executive appointments in commercial operations including sales, marketing, managed care and customer support.

Forming drug delivery business unit with the addition of experienced senior executives.

Extending exclusive blood glucose meter partnership with Abbott Laboratories.

Transforming Canadian distribution to a direct model for OmniPod.

Insulet Corporation(NASDAQ:PODD)started its trading session with the price of $ 30.61 and closed at $ 31.31 by scoring + 2.72 % and traded with total volume of 1.22M shares, while the average trading remained 681,886.00 shares. During last trade its minimum price was $ 30.49 and it gained the highest price of $ 31.48. Its market capitalization was $ 1.73B.

Plasmatech Biopharmaceuticals Inc(NASDAQ:PTBI) accomplished its acquisition of Abeona Therapeutics LLC, an Ohio limited liability company (“Abeona”) following the terms of a contract and Plan of Merger, dated as of May 5, 2015, the execution of which was formerly revealed in a Current Report on Form 8-K filed by PlasmaTech on May 6, 2015 (the “Acquisition”).

In connection with the Acquisition, PlasmaTech will issue an aggregate of 3,979,761 shares of PlasmaTech’s common stock to the members of Abeona. In addition, there may be up to an additional $9 million in performance milestones payable to members of Abeona, in common stock or cash, at PlasmaTech’s option.

PlasmaTech will file with the Securities and Exchange Commission (the “SEC”) the financial statements and pro forma financial information required to be filed following Rule 3-05 of Regulation S-X and Article 11 of Regulation S-X within 71 days after the date on which this Current Report on Form 8-K was required to be filed with the SEC.

Plasmatech Biopharmaceuticals Inc(NASDAQ:PTBI)showing dropped of -5.50% and closed at $ 6.53, after gaining total volume of 1.21M shares. Its opening price was $ 6.90. Its earnings per share(EPS) is $ -31.55 and its beta value stands at 0.56 points and has total market capitalization of $ 167.69M and a total of 24.27M outstanding shares.

Cempra Inc(NASDAQ:CEMP) a clinical-stage pharmaceutical company, emphases on developing antibiotics to meet critical medical needs in the treatment of bacterial infections ailments in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections.

Cempra Inc(NASDAQ:CEMP) reported the surge of 7.36% and closed at $ 35.30 , with the total traded volume of 1.21M shares and opening price was $ 33.04. During last trade its minimum price was $ 32.90 and it gained its highest price of $ 35.48 and has a total of 43.59M outstanding shares and its total market capitalization is $1.43B.

China Cord Blood Corp(NYSE:CO) China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that the Special Committee of the Company’s board of directors (the “Special Committee”) has appointed Houlihan Lokey (China) Limited as its independent financial advisor, Cleary Gottlieb Steen & Hamilton LLP as its United States legal counsel and Maples & Calder as its Cayman Islands legal counsel.

As previously announced, the Company’s board of directors formed the Special Committee to review and evaluate the April 27, 2015 non-binding proposal from Golden Meditech Holdings Limited (“Golden Meditech”) to acquire all of the outstanding ordinary shares of the Company not already directly or indirectly owned by Golden Meditech in a “going private” transaction.

China Cord Blood Corp(NYSE:CO) reported the decline of -3.58%, after closing price for the day was $ 6.20 and opening at the price of $ 6.45 . Its total trading volume for the day was 1.20M shares, versus its average volume of 246,859.00 shares. Its earnings per share are $ 0.28.